AbbVie Inc. (AbbVie) is a diversified research-based biopharmaceutical company. The Company is engaged in the research and development, manufacturing, commercialization and sale of medicines and therapies. It offers products in various therapeutic categories, including immunology products, which include Humira, Skyrizi and Rinvoq; oncology products, which include Imbruvica and Venclexta/Venclyxto; aesthetics products that include Botox Cosmetic, The Juvederm Collection of Fillers and others; neuroscience products, such as Botox Therapeutic, Vraylar, Duopa and Duodopa, and Ubrelvy; eye care products, which consists of Lumigan/Ganfort, Alphagan/Combigan and Restasis, and other key products, which include Mavyret/Maviret, Creon, Lupron, Linzess/Constella and Synthroid. Its products are sold to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from the AbbVie-owned distribution centers and public warehouses.
TD Ameritrade displays two types of stock earnings numbers, which are calculated differently and may report different values for the same period. GAAP earnings are the official numbers reported by a company, and non-GAAP earnings are adjusted to be more readable in earnings history and forecasts.
|Date||Event description||Earnings per|
|April 27, 2023||Q1 2023 Earnings Release||$2.46||$2.36 to $2.64||$3.16|
|February 9, 2023||Q4 2022 Earnings Release||$3.60||$3.51 to $3.66||$3.08|
|October 28, 2022||Q3 2022 Earnings Release||$3.66||$3.51 to $3.70||$2.83|
|July 29, 2022||Q2 2022 Earnings Release||$3.37||$3.21 to $3.49||$3.03|
|Ex-dividend date||Amount||Record date||Pay date|
|April 13, 2023||$1.48||April 14, 2023||May 15, 2023|
|January 12, 2023||$1.48||January 13, 2023||February 15, 2023|
|October 13, 2022||$1.41||October 14, 2022||November 15, 2022|
|July 14, 2022||$1.41||July 15, 2022||August 15, 2022|
, , , Copyright © 2023. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.